We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit
BIOTU

Delisted

BIOTU was delisted on the 2nd of February, 2023.

Back to rankings

41 hedge funds and large institutions have $60.1M invested in Biotech Acquisition Company Unit in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

31% less funds holding

Funds holding: 59 → 41 (-18)

49% less capital invested

Capital invested by funds: $118M → $60.1M (-$58.2M)

82% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 22

Holders
41
Holders Change
-18
Holders Change %
-30.51%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
8
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
Rivernorth Capital Management
Florida
+$1.93M
2
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$1.5M
3
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
+$538K
4
SMA
Sage Mountain Advisors
Georgia
+$230K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$167K

Top Sellers

Rank Fund Capital Flow
1
BCM
BlueCrest Capital Management
Jersey
-$9.89M
2
LA
Linden Advisors
New York
-$6.71M
3
PC
Periscope Capital
Ontario, Canada
-$4.91M
4
DCM
DG Capital Management
New York
-$4.45M
5
RCM
Radcliffe Capital Management
Pennsylvania
-$4.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
COPPSERS
26
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$403K +$150K +15,000 +60%
RA
27
Ramius Advisors
New York
$340K -$544K -54,273 -62%
BCM
28
BCK Capital Management
Connecticut
$269K – – –
GCIA
29
Gabelli & Co Investment Advisers
New York
$256K – – –
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$252K -$4.75K -474 -2%
GF
31
Gabelli Funds
New York
$247K – – –
LCM
32
Landscape Capital Management
New Jersey
$222K +$96.4K +9,618 +77%
OCAM
33
Owl Creek Asset Management
New York
$202K – – –
DIG
34
DeepCurrents Investment Group
New York
$179K -$72.8K -7,270 -29%
BFM
35
Boothbay Fund Management
New York
$152K +$151K +15,030 New
VCM
36
Vivaldi Capital Management
Illinois
$101K – – –
Morgan Stanley
37
Morgan Stanley
New York
$100K – – –
BCM
38
Basso Capital Management
Connecticut
$42K – – –
UBS Group
39
UBS Group
Switzerland
$18K -$5.89K -588 -24%
MF
40
Magnetar Financial
Illinois
$4.47K +$45.1K +4,500 +1%
Walleye Capital
41
Walleye Capital
New York
$1.21K – – –
BCM
42
BlueCrest Capital Management
Jersey
– -$9.89M -1,000,000 Closed
LA
43
Linden Advisors
New York
– -$6.71M -678,849 Closed
PC
44
Periscope Capital
Ontario, Canada
– -$4.91M -496,846 Closed
DCM
45
DG Capital Management
New York
– -$4.45M -450,000 Closed
RCM
46
Radcliffe Capital Management
Pennsylvania
– -$4.01M -405,900 Closed
Nomura Holdings
47
Nomura Holdings
Japan
– -$3.98M -400,137 Closed
KSCM
48
Kamunting Street Capital Management
Florida
– -$3.14M -317,924 Closed
DKCM
49
Davidson Kempner Capital Management
New York
– -$2.96M -300,000 Closed
Deutsche Bank
50
Deutsche Bank
Germany
– -$2.73M -275,714 Closed
1
2
3

BIOTU Hedge Fund Activity: Q2 2021 in Review

41 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q2 2021, worth a combined $60.1M — down 49% from $118M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BIOTU and 4 opened new positions — a net loss of 18 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Rivernorth Capital Management, adding an estimated $1.93M. The largest seller was BlueCrest Capital Management, exiting entirely with an estimated $9.89M sold.

  • 41 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q2 2021, down from 59 in Q1 2021.
  • Funds reported $60.1M of Biotech Acquisition Company Unit stock for Q2 2021, down 49% quarter-over-quarter.
  • 4 funds opened new Biotech Acquisition Company Unit positions in Q2 2021 and 22 closed out, a net change of -18 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q2 2021 was Rivernorth Capital Management, an estimated $1.93M added.
  • The largest Biotech Acquisition Company Unit seller in Q2 2021 was BlueCrest Capital Management, an estimated $9.89M sold.

Based on aggregated 13F filings for Q2 2021.